Clinical Trial Update: IVIG Treatment for Refractory Immune-Related Adult Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 trial of intravenous immunoglobulin (IVIG) for refractory immune-related epilepsy was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Encephalitis
• Epilepsy
• Limbic Encephalitis

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)

Snippet

Sponsor: Emory University | Conditions: Epilepsy, Cryptogenic, Epilepsy, Partial | Phase 2 | Status: TERMINATED | Results posted: 2014-09-01